Epilepsy

Children exposed in utero to valproate were most affected, but exposure to 3 other monotherapies were also associated with behavioral issues.

FDA approved midazolam nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.

How can emergency department doctors best be prepared to identify and treat seizures in the ER?

Investigators studied patients from 5 unrelated families to determine the genetic mutations causing the condition.

Research into a rare neurological disorder may help researchers working on more common diseases including autism and epilepsy.

Characterizing these pediatric epilepsy readmissions is the first step in reducing readmissions, study authors said.

Results suggest that pediatric patients with epilepsy should have genomic test results reinterpreted at least every 2 years and before further genetic testing.

A cross-validated, stratified cohort found that certain epilepsy patient populations could be at a two-fold greater risk of AED-related psychiatric effects.

Largest observational study on antiepileptic treatment for poststroke epilepsy finds highest adherence to a less frequently prescribed drug.

Investigators found atypical responses from brain cells known as astrocytes, which follow traumatic brain injuries (TBIs), may be the cause of epilepsy development.

A delay in giving the first dose of an antiepileptic for pediatric status epilepticus is common and associated with increased seizure duration.

A prediction model helps determine the probability of childhood epilepsy in first consultation after a paroxysmal event.

This is the first generic approval of the tablet form of vigabatrin, which is indicated for treating focal seizures in patients with epilepsy.

A noninvasive and age-specific test could facilitate surgery for focal epilepsy in children.

A retrospective study showed which patients with substance use disorder may have less successful antiepileptic drug treatment.

Over 2 years, lacosamide was effective and generally well tolerated among adults with newly diagnosed epilepsy, compared to carbamazepine.

The FDA has expanded approval for the Embrace smartband to be used by children aged 6 years and older with epilepsy.